StockNews.com Begins Coverage on Trevena (NASDAQ:TRVN)

StockNews.com started coverage on shares of Trevena (NASDAQ:TRVN) in a research report report published on Sunday. The brokerage issued a sell rating on the biopharmaceutical company’s stock.

Separately, HC Wainwright cut their price target on shares of Trevena from $9.00 to $5.00 and set a buy rating on the stock in a report on Thursday, May 16th.

Trevena Price Performance

TRVN opened at $0.20 on Friday. The firm has a market capitalization of $3.62 million, a PE ratio of -0.07 and a beta of 1.05. Trevena has a fifty-two week low of $0.17 and a fifty-two week high of $1.12. The company’s 50-day moving average is $0.28 and its 200 day moving average is $0.42.

Trevena (NASDAQ:TRVN) last announced its earnings results on Wednesday, May 15th. The biopharmaceutical company reported ($0.36) EPS for the quarter, beating the consensus estimate of ($0.37) by $0.01. The firm had revenue of $0.02 million during the quarter. As a group, analysts expect that Trevena will post -1.29 EPS for the current year.

Institutional Trading of Trevena

A hedge fund recently bought a new stake in Trevena stock. Armistice Capital LLC bought a new position in shares of Trevena, Inc. (NASDAQ:TRVN) during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor bought 797,714 shares of the biopharmaceutical company’s stock, valued at approximately $576,000. Armistice Capital LLC owned approximately 4.61% of Trevena at the end of the most recent reporting period. 13.56% of the stock is currently owned by institutional investors.

About Trevena

Trevena, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel medicines for patients affected by central nervous system disorders. Its lead product candidates include OLINVYK (Oliceridine) injection, a G protein biased mu-opioid receptor (MOR) ligand for the management of moderate-to-severe acute pain; TRV250, a G protein biased delta-opioid receptor agonist for the treatment of acute migraine; TRV734, a small molecule G protein biased ligand of the MOR for the treatment of moderate-to-severe acute and chronic pain; and TRV045, a novel S1P modulator for managing chronic pain.